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This data is related to our paper “Small molecules preventing
GAPDH aggregation are therapeutically applicable in cell and rat
models of oxidative stress” (Lazarev et al. [1]) where we explore
therapeutic properties of small molecules preventing GAPDH
aggregation in cell and rat models of oxidative stress. The present
article demonstrates a few of additional properties of the chemi-
cals shown to block GAPDH aggregation such as calculated site for
targeting the enzyme, effects on GAPDH glycolytic activity, inﬂu-
ence on GAPDH intracellular level and anti-aggregate activity of
pure polyglutamine exemplifying a denatured protein.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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ject areaBiology of oxidative stressype of data Text ﬁle, ﬁgure, images
ow data was
acquiredMolecular docking, Western blot, Dot blot, Microscope, Survey, Spectrometryata format Analyzed
xperimental
factorsPure GAPDH and polyglutamine were used in in vitro experimentsxperimental
featuresSmall molecules preventing GAPDH aggregation do not affect glycolytic
activity of the enzyme, its intracellular level and do not suppress poly-
glutamine aggregation.ata source
locationSt. Petersburg, Russiaata accessibility The data is supplied with this articleValue of the data The current paper presents a new GAPDH binders preventing its aggregation.
 To ﬁnd the site of interaction between small molecules and GAPDH the molecular docking method
was applied.
 This data article describes a set of methods to determine the speciﬁcity of interaction between
protein and ligands, the impact of drugs on the state of the protein in the cell and the enzyme
activity of target protein.1. Data
The data presented in this article demonstrate the biochemical characteristics of the substances
previously shown as blockers of GAPDH aggregation. Among other things, it contains data of mole-
cular docking of these substances and the measurements of GAPDH enzymatic activity in the pre-
sence of the ligands.2. Experimental design, materials and methods
2.1. Molecular docking
Early we found a group of substances that inhibit the aggregation of oxidized GAPDH [1]. To reveal
the site of GAPDH molecule targeted by the selected substances (RX409, RX426, RX624, RX625, and
RX648) the method of molecular docking was employed (Fig. 1). Molecular docking was performed
using Lead Finder software [2]. The structures of ligands were built using ChemSketch (www.acdlabs.
com).
2.2. Measurement of GAPDH enzymatic activity
Next we analyzed the effect of the ﬁve selected compounds on GAPDH enzymatic activity. Only
RX648 was shown to reduce the enzymatic activity of GAPDH (Fig. 2). The effects of selected
Fig. 1. Ligands bind GAPDH molecule in its active site. Figure represents the most probably positions of GAPDH binders.
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experiments were carried out at 25 °C using a UV-1601 Shimadzu spectrometer (Shimadzu Scientiﬁc
Instruments Inc., Japan).Fig. 3. The selected compounds does not affect GAPDH level in SK-N-SH cells treated with hydrogen peroxide. Data of
immunoblotting are presented. DMSO was used as the control for solvent. Staining with anti-Tubulin antibodies was used for
the loading control.
Fig. 4. The effect of selected compounds on polyglutamine aggregation. Data of ultraﬁltration are shown. Anti-polyglutamine
antibodies were used. DMSO presented as the solvent.
Fig. 2. The effect of selected compounds on enzymatic activity of GAPDH. The GAPDH activity values were obtained after 15-
min incubation of GAPDH 0.1 mg/ml in the presence of 0.1 mM ligands in PBS. DMSO was used as the control for solvent.
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To conﬁrm the enzyme stability in vitrowe analyzed its content in SK-N-SH human neuroblastoma
cells incubated with chemicals in concentration of 1 mM for 24 h; the analysis was performed with the
aid of immunoblotting using 6C5 antibody and its data show the constancy of GAPDH level in cells
irrespective of whether they were treated or not (Fig. 3).
2.4. Dot ultraﬁltration
Ability of GAPDH binders to prevent the enzyme aggregation speciﬁcally was established in
experiments with polyglutamine (Q58). The polypeptide known to form aggregates [4] was incubated
with ﬁve selected compounds and the mixture after 24-h incubation was subjected to dot ultra-
ﬁltration. Anti-polyglutamine antibody (Abcam, UK) was used to stain the resulting membrane. All
compounds except for RX625 were not able to suppress the aggregate-formation processes (Fig. 4).Acknowledgments
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